Low-Code Meets Cloud Smart: Claris Expands FileMaker Cloud to EMEA Markets
Claris International Inc., an Apple subsidiary and pioneering leader in low-code, today announced the official launch of FileMaker Cloud to EMEA markets. FileMaker Cloud gives EMEA businesses all of the power of the cloud - sharing, rapid deployment, scalability - without compromising on performance or losing connection to the real world of devices, sensors, even offline apps. The result is a future-proof solution that empowers businesses to rapidly create and share intelligent apps with their teams, and integrate them with other popular apps and web services.
“For so many businesses, the global pandemic changed every aspect of their business overnight, which led to a massive boom in both low-code adoption and remote work technologies,” said Brad Freitag, CEO of Claris. “In many ways, Claris was built for this moment. Our commitment to low-code without limits - quickly deploying intelligent apps that both solve and evolve - means the solutions our customers build to deal with today’s changes can serve as their IT backbone going forward. We’re thrilled to finally bring FileMaker Cloud to EMEA as we continue to power the workplace of tomorrow through limitless and scalable low-code solutions.”
Designed to augment its widely adopted Claris Platform, FileMaker Cloud offers localised infrastructure to assist businesses with implementing General Data Protection Regulation (GDPR) and German Bundesdatenschutzgesetz (BDSG) compliance, while also providing a scalable, agile, and adaptable solution to drive IT impact in EMEA. The FileMaker Cloud solution also brings emerging technologies within reach, ready to leverage artificial intelligence (AI), machine learning (ML), digital assistants, Internet of Things, augmented and virtual reality, and whatever comes next.
FileMaker Cloud offers the following capabilities:
- Agility and speed: Ability to rapidly deploy within an organisation without software or hardware. Start creating and sharing custom apps 4x faster.
- Streamlined management: Easily manage users and groups in one secure place, including full tracking, and visibility.
- Privacy, security and support: Provides end-to-end encryption, multi-factor authentication, and dedicated 24/7 support and monitoring by expert teams to ensure premium security and performance.
- Hassle-free infrastructure: Access to fully configured hardware and installed software, as well as automated server maintenance.
- Future-proof scalability: Ability to rapidly scale across departments and entire businesses for fast-paced growth.
- Affordable, set prices: Yearly subscription fee of €41 EUR per month, available for purchase in local currency.
- Certificates: Built-in SSL certificate included with the service.
- Local language support: Access to multiple languages, including French, Italian, German, and Spanish.
For more information or to purchase FileMaker Cloud, please visit store.filemaker.com.
About Claris International Inc.
Claris International Inc. is the creator of the world's leading rapid, low-code development platform, offering a suite of services that empower problem solvers to drive digital transformation in businesses large and small. The company has more than 1.3 million active users globally across SMBs and the Fortune 500. Claris is an Apple subsidiary with an unmatched record of business success of more than 80 consecutive profitable quarters. Claris is headquartered in California with operations worldwide, including London, Paris, Munich, Tokyo, Beijing, and Sydney.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027006244/en/
Contact information
Erin Healey
claris@clarity.pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom